Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.93), $0.09 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $26 million versus the consensus estimate of $24.27 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.